Skip to main content

Advertisement

Log in

Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience

Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The aim of the present study was to consider the safety and efficacy of concurrent use of strontium-89 (Sr-89) with external beam radiotherapy (EBRT) for multiple bone metastases, including lesions that require urgent therapy.

Methods

A retrospective review was performed of a consecutive series of patients who received Sr-89 for multiple bone metastases. Forty-five patients with multiple bone metastases received Sr-89 injection. Since 17 of the 45 patients had osteolytic bone lesions requiring emergent EBRT, they underwent concurrent use of Sr-89 with EBRT (concurrent group). The remaining 28 patients, none of whom had osteolytic lesions requiring urgent EBRT, were given Sr-89 injection only (singularity group). The injection of Sr-89 was to be given during EBRT, or on the day before the first day of EBRT. The dose of EBRT was 30 Gy in 10 fractions or 40 Gy in 20 fractions. Adverse events were evaluated according to hematological toxicity as measured by the Common Terminology Criteria for Adverse Events (V4.0). To assess efficacy, we checked changes in the pain scale and analgesic drug dosages, and the presence or absence of serious complications from bone metastases.

Results

Fifteen of 17 patients (88.2 %) in the concurrent group and 17 of 28 patients (60.7 %) in the singularity group reported bone pain relief. A statistically significant difference was found between the two groups, and severe complications (spinal cord compression and pathological fracture) from bone metastases could be prevented in all patients in the concurrent group. Severe hematological toxicity (grade 3 or higher) was not observed in the two groups. There was no statistical difference between the two groups. No one required additional intervention. The adverse events were tolerable.

Conclusions

The results of our study suggest that concurrent use of Sr-89 with EBRT for multiple bone metastases can be performed safely if it is carried out with care, and that it may be an effective therapy in cases requiring emergency treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6:392–400.

    Article  CAS  PubMed  Google Scholar 

  2. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group. Cancer. 1982;50:893–9.

    Article  CAS  PubMed  Google Scholar 

  3. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Kohno N. Treatment of breast cancer with bone metastasis: bisphosphonate treatment-current and future. Int J Clin Oncol. 2008;13:18–23.

    Article  CAS  PubMed  Google Scholar 

  5. Bruckman JE, Bloomer WD. Management of spinal cord compression. Semin Oncol. 1978;5:134–40.

    Google Scholar 

  6. Gilbert RW, Kim JH. Posner. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 1978;3:40–51.

    Article  CAS  PubMed  Google Scholar 

  7. Ruff RL, Lanska DJ. Epidural metastases in prospectively evaluated veterans with cancer and back pain. Cancer. 1989;63:2234–41.

    Article  CAS  PubMed  Google Scholar 

  8. McEwan AJ. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med. 1997;27:165–82.

    Article  CAS  PubMed  Google Scholar 

  9. Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun. 2007;28:245–50.

    Article  PubMed  Google Scholar 

  10. Lipton A, Costa L, Ali SM, Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev. 2001;27:181–5.

    Article  CAS  PubMed  Google Scholar 

  11. Serafini AN. Current status of bone pain palliation with systemic radioisotopes. Nucl Med Ann. 2002;1:253–74.

    Google Scholar 

  12. Soerdjbalie-Maikoe V, Pelger RC, Lycklama a Nijeholt GA, Arndt JW, Zwinderman AH, Papapoulos SE, et al. Strontium-89(Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging. 2002;29:494–8.

    Article  CAS  PubMed  Google Scholar 

  13. Yamada K, Yoshimura M, Kaise H, Ogata A, Ueda N, Tokuuye K, et al. Concurrent use of Sr-89 chloride with zoledronic acid is safe and effective for breast cancer patients with painful bone metastases. Exp Ther Med. 2012;3:226–30.

    PubMed Central  CAS  PubMed  Google Scholar 

  14. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–13.

    Article  CAS  PubMed  Google Scholar 

  15. McEwan AJ, Porter AT, Venner P, Amyotte G. An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy. Antibody Immunoconjugates Radiopharmaceuticals. 1990;3:91–7.

    Google Scholar 

  16. Society of Nuclear Medicine Procedure Guideline for Palliative Treatment of Painful Bone Metastases ver.3.0 (http://interactive.snm.org/docs/pg_ch25_0403.pdf). Accessed 5 Aug 2015.

  17. Silberstein EB, Taylor AT Jr, EANM. EANM procedure guidelines for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2003;30:BP7–11.

    Article  PubMed  Google Scholar 

  18. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Logothetis CJ, et al. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy. J Clin Oncol. 2005;23:7904–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to Keiichiro Yamaguchi, Vice president of Sendai Kousei Hospital, for his guidance on the proper use of Sr-89.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joichi Heianna.

Ethics declarations

Conflict of interest

There are no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heianna, J., Toita, T., Endo, W. et al. Concurrent use of strontium-89 with external beam radiotherapy for multiple bone metastases: early experience. Ann Nucl Med 29, 848–853 (2015). https://doi.org/10.1007/s12149-015-1010-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-015-1010-6

Keywords

Navigation